Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

HEU-EFS Harmonised Approach to Early Feasibility Studies for Medical Devices in the European Union

Coordinator
Universita Commerciale Luigi Bocconi, Italy
Runs
1 October 2023 to 30 September 2027
Status
Running
EU funding
€10.5m
Total cost
€19.1m
Partners
41 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101112185

What the project is doing

In the project's own words, from its summary on CORDIS.

EU Regulations on medical devices (MDs), in-vitro diagnostics, and Health Technology Assessment envisage a harmonised lifecycle approach for clinical evidence generation of MDs. To be effective this approach requires evidence generation plan to be developed since early stages of product development, by engaging all relevant stakeholders. At present, in the EU there are no standardized procedural frameworks/guidelines/common reference standards for Early Feasibility Studies (EFS), clinical investigations allowed by ISO 14155:2020 conducted early in the development aiming to inform the product development.

The ambition of the HEU-EFS project is to develop a harmonised framework for the EU EFS Program, as one integrated step of evidence generation cycle. Project objectives include: (1) conducting research/analysis on state of play (i.e., characteristics, challenges, impacts) of pre-market programs for MDs, including EFS; (2) building a sustainable network of stakeholders at EU/national level to promote/support EFS implementation; (3) developing a sound, widely applicable, harmonised EU methodology and formulating recommendations to uptake EFS; (4) undertaking pilots to test the proposed framework; (5) developing instruments to monitor the EFS performance; and (6) implementing a dedicated, sustainable, open access online portal dedicated to EFS methodological framework, best practices and network.

To achieve these goals, the HEU-EFS consortium has been designed including a wide range of relevant stakeholders: research organisations, HTA bodies, patient organizations, healthcare providers, SMEs (including health technology developers, legal experts, and a CRO), and 6 major private companies that are part of a pre-identified industry consortium. An Advisory Board made of competent authorities, notified bodies, medical and biomedical engineering professional associations, networks and industry trade association will collaborate to the success of the initiative.

Topics

Who is involved

OrganisationCityCountryRole
Universita Commerciale Luigi BocconiMilanoItalyCoordinator
Abbott Vascular InternationalMachelenBelgiumParticipant
Edwards Lifesciences Belgium BVDilbeekBelgiumParticipant
Forum Des Patients EuropeensBruxelles / BrusselBelgiumParticipant
St Jude Medical Coordination CenterZaventemBelgiumThird party
Edwards Lifesciences SARLNyonSwitzerlandThird party
Synthes GmbHOberdorf BlSwitzerlandParticipant
Edwards Lifesciences GmbHGarching B. MunchenGermanyThird party
Philipps Universitaet MarburgMarburgGermanyParticipant
Qurasoft GmbHKoblenzGermanyParticipant
Region SyddanmarkVejleDenmarkParticipant
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Medtronic Iberica SAMadridSpainThird party
Abbott FranceRungis CedexFranceThird party
Assistance Publique Hopitaux De ParisParisFranceParticipant
CarmatVelizy-VillacoublayFranceParticipant
Edwards Lifesciences SASGuyancourtFranceThird party
Sofradim Production SasuTrevouxFranceThird party
Global Heart Hub Company Limited by GuaranteeGalwayIrelandParticipant
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
University of GalwayGalwayIrelandParticipant
Abbott Medical Italia SRLSesto San Giovanni - MiItalyThird party
Agenzia Nazionale per I Servizi Sanitari RegionaliRomaItalyParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Meditrial S.r.l.RomaItalyParticipant
Newronika SpAMilanoItalyParticipant
W.l. Gore & Associati S.r.l.VeronaItalyParticipant
Abbott BVHoofddorpNetherlandsThird party
Edwards Lifesciences BVBredaNetherlandsThird party
Idris Oncology B.v.LeidenNetherlandsParticipant
Medtronic Bakken Research Center B.v.MaastrichtNetherlandsParticipant
Philips Medical Systems Nederland BVBestNetherlandsParticipant
W L Gore & Associates BVTilburgNetherlandsThird party
FolkehelseinstituttetOsloNorwayParticipant
Abbott Laboratorios LdaAmadoraPortugalThird party
Abbott Laboratories LimitedBerkshireUnited KingdomThird party
Edwards Lifesciences LlcIrvine CaliforniaUnited StatesThird party
Evalve, IncWilmingtonUnited StatesThird party
St Jude Medical Business Services IncWilmingtonUnited StatesThird party
St Jude Medical Cardiology Division IncWilmington DelawareUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI